Table 1.
Baseline characteristics of the cohort.
Table 2.
Hazard ratios for clinical outcomes stratified by categories of eGFR in ml/min/1.73 m2.
Figure 1.
Receiver Operating Characteristic curves of CKD-EPI creatinine, CKD-EPI cystatin C and CKD-EPI creatinine-cystatin C eGFR equations for all-cause mortality.
Fully adjusted models include body mass index, previous cardiovascular disease, previous renal disease, anti-hypertensive medications, diabetes, smoking history and treatment code.
Figure 2.
Receiver Operating Characteristic curves of CKD-EPI creatinine, CKD-EPI cystatin C and CKD-EPI creatinine-cystatin C eGFR equations for cardiovascular disease hospitalization and/or mortality.
Fully adjusted models include body mass index, previous cardiovascular disease, previous renal disease, anti-hypertensive medications, diabetes, smoking history and treatment code.
Figure 3.
Correlation of the predicted probabilities for cardiovascular disease hospitalization and/or mortality of CKD-EPI creatinine and CKD-EPI creatinine-cystatin C equations.
Fully adjusted models include body mass index, previous cardiovascular disease, previous renal disease, anti-hypertensive medications, diabetes, smoking history and treatment code.
Figure 4.
Correlation of the predicted probabilities for all-cause mortality of CKD-EPI creatinine and CKD-EPI creatinine-cystatin C equations.
Fully adjusted models include body mass index, previous cardiovascular disease, previous renal disease, anti-hypertensive medications, diabetes, smoking history and treatment code.
Table 3.
Net reclassification improvement of eGFR categories for all-cause mortality and cardiovascular disease hospitalization and/or mortality using CKD-EPI cystatin C equation compared with CKD-EPI creatinine equation.
Table 4.
Net reclassification improvement of eGFR categories for all-cause mortality and cardiovascular disease hospitalization and/or mortality using CKD-EPI creatinine-cystatin C equation compared with CKD-EPI creatinine equation.